Dogwood Therapeutics Reports Q3 Net Loss of $4.88M, Down from $15.74M
Dogwood Therapeutics, Inc. filed its quarterly report on Form 10-Q for the period ending September 30, 2026. The company reported a net loss of $4.88 million for the third quarter of 2026, a significant improvement from a net loss of $15.74 million in the same period of 2025. For the nine-month period, the net loss was $21.40 million, down from $30.48 million in 2025. Total assets and liabilities both decreased compared to the end of the previous fiscal year. The company generated $100,000 in licensing revenue during the period. However, the report highlights substantial doubt about the company's ability to continue as a going concern, stating that additional financing is required to fund operations beyond the first quarter of 2027.
Key Highlights
- Dogwood Therapeutics reported a net loss of $4.88 million for Q3 2026, compared to $15.74 million in Q3 2025.
- For the nine months ended September 30, 2026, net loss was $21.40 million, a decrease from $30.48 million in the same period of 2025.
- Total assets decreased to $75.61 million as of September 30, 2026, from $90.17 million as of December 31, 2025.
- Total liabilities decreased to $11.48 million as of September 30, 2026, from $15.27 million as of December 31, 2025.
- Licensing revenue of $100,000 was recognized in Q3 2026 and the nine months ended September 30, 2026.
- Research and development expenses for Q3 2026 were $3.35 million, down from $14.52 million in Q3 2025.
- The company has substantial doubt about its ability to continue as a going concern within one year.
- Dogwood Therapeutics will need to secure additional financing to fund operations beyond Q1 2027.
Price Impact
More from DWTX
Dogwood Therapeutics Q2 Net Loss $11.5M; Halneuron® Phase 2b on track
Dogwood Therapeutics Halneuron® Phase 2b On Track; Antiviral Deal Up To $100M
Dogwood Therapeutics Appoints Iain Dukes as Chair of New SAB